156 related articles for article (PubMed ID: 11846062)
1. Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer.
Takahashi S; Kinoshita T; Konishi M; Nakagouri T; Inoue K; Ono M; Sugitou M; Ohtsu A; Boku N; Yoshida S
Gastric Cancer; 2001; 4(4):192-7. PubMed ID: 11846062
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002).
Kinoshita T; Sasako M; Sano T; Katai H; Furukawa H; Tsuburaya A; Miyashiro I; Kaji M; Ninomiya M
Gastric Cancer; 2009; 12(1):37-42. PubMed ID: 19390930
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Bjarnason GA; Cripps C; Goel R; Fine S; Oza AM; Skillings JR; Kerr I; Germond CJ; Moore MJ; Maroun JA; Franssen E; Dulude H
Am J Clin Oncol; 1998 Dec; 21(6):537-42. PubMed ID: 9856651
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
[TBL] [Abstract][Full Text] [Related]
6. Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
Kunisaki C; Makino H; Kimura J; Takagawa R; Kanazawa A; Ota M; Kosaka T; Ono HA; Akiyama H; Endo I
Oncology; 2015; 88(5):281-8. PubMed ID: 25591954
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.
Gallardo-Rincón D; Oñate-Ocaña LF; Calderillo-Ruiz G
Ann Surg Oncol; 2000; 7(1):45-50. PubMed ID: 10674448
[TBL] [Abstract][Full Text] [Related]
8. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
Murad AM; Santiago FF; Petroianu A; Rocha PR; Rodrigues MA; Rausch M
Cancer; 1993 Jul; 72(1):37-41. PubMed ID: 8508427
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Cocconi G; Carlini P; Gamboni A; Gasperoni S; Rodinò C; Zironi S; Bisagni G; Porrozzi S; Cognetti F; Di Costanzo F; Canaletti R; Ruggeri EM; Camisa R; Pucci F;
Ann Oncol; 2003 Aug; 14(8):1258-63. PubMed ID: 12881389
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers.
Abe S; Kubota T; Matsuzaki SW; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M
Anticancer Res; 1999; 19(5C):4581-6. PubMed ID: 10650814
[TBL] [Abstract][Full Text] [Related]
11. Postsurgical sequential methotrexate, fluorouracil, and leucovorin for stages 3 and 4 gastric carcinoma: A preliminary study.
Tokunaga Y; Kitaoka A; Yagi T; Tokuka A; Ohsumi K
J Surg Oncol; 2000 Sep; 75(1):31-6. PubMed ID: 11025459
[TBL] [Abstract][Full Text] [Related]
12. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
Hartgrink HH; van de Velde CJ; Putter H; Songun I; Tesselaar ME; Kranenbarg EK; de Vries JE; Wils JA; van der Bijl J; van Krieken JH;
Eur J Surg Oncol; 2004 Aug; 30(6):643-9. PubMed ID: 15256239
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
[TBL] [Abstract][Full Text] [Related]
15. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Shirao K; Boku N; Yamada Y; Yamaguchi K; Doi T; Goto M; Nasu J; Denda T; Hamamoto Y; Takashima A; Fukuda H; Ohtsu A;
Jpn J Clin Oncol; 2013 Oct; 43(10):972-80. PubMed ID: 24014884
[TBL] [Abstract][Full Text] [Related]
17. [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Zhao Q; Li Y; Tan BB; Tian Y; Jiao ZK; Zhao XF; Zhang ZD; Wang D; Yang PG
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):773-7. PubMed ID: 24378101
[TBL] [Abstract][Full Text] [Related]
18. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study.
Tahara M; Ohtsu A; Boku N; Nagashima F; Muto M; Sano Y; Yoshida M; Mera K; Hironaka S; Tajiri H; Yoshida S
Gastric Cancer; 2001; 4(4):212-8. PubMed ID: 11846065
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.
Ajani JA; Goudeau P; Levin B; Faintuch JS; Abbruzzese JL; Boman BM; Kanojia MD
Cancer Chemother Pharmacol; 1989; 24(1):41-4. PubMed ID: 2720890
[TBL] [Abstract][Full Text] [Related]
20. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
